Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.30B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 3.38M
Average 2.73M
TSHA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Taysha Gene Therapies, Inc.NASDAQ: TSHA
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue remains negative
Q2 FY2026 revenue was $0, compared with $1.99M a year earlier. Trailing-twelve-month revenue was $5.49M. Over 3 fiscal years it compounded at +57.5% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $1.64M (-83.3%) for the fiscal year ending Dec 2026, a slowdown from the +17.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $0— QoQ
- Last fiscal yearDec 2025
- $9.77M+17.3% YoY
- LTMJun 2026
- $5.49M-32.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -100.0% | — | — |
| 1 year | +17.3% | -83.3% | -100.5 pp |
| 3-year CAGR | +57.5% | +147.7% | +90.2 pp |
| 5-year CAGR | +154.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 9.77M USD
- Year-over-year change
- +17.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.77M | +17.3% |
| FY2024 | 2024-12-31 | 8.33M | -46.1% |
| FY2023 | 2023-12-31 | 15.45M | +517.5% |
| FY2022 | 2022-12-31 | 2.5M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How TSHA compares with its peers on the latest reported figures
- TSHA's LTM Jun 2026 revenue of $5.49M is the 6th highest of the 9 companies compared; the peer median is $25.52M.
- Its year-over-year change of -32.3% is the 3rd highest of 6, against a peer median of -44.0%.
- Over three fiscal years its annual growth of +57.5% compares with a peer median of +33.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.18B | -2.2% | +33.1% | |
| LTM Mar 2026 | $88.24M | +383560.9% | +200.9% | |
| LTM Mar 2026 | $87.82M | -44.0% | +14.8% | |
| LTM Mar 2026 | $36.49M | -45.5% | -0.4% | |
| LTM Mar 2026 | $14.54M | — | +60.3% | |
| LTM Jun 2026 | $5.49M | -32.3% | +57.5% | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding TSHA) | $25.52M | -44.0% | +33.1% | |
Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.5M | 15.45M | 8.33M | 9.77M |
| Cost of Revenue | 0 | 2.49M | 0 | 0 | 0 |
| Gross Profit | 0 | 15K | 15.45M | 8.33M | 9.77M |
| Gross Margin | — | 0.6% | 100.0% | 100.0% | 100.0% |
| Research & Development | 131.94M | 91.17M | 56.78M | 66M | 86.4M |
| Selling, General & Admin | 41.32M | 34.87M | 30.05M | 28.95M | 33.87M |
| Operating Expenses | 173.27M | 126.04M | 87.89M | 99.79M | 120.27M |
| Depreciation & Amortization | 492K | 2.49M | 1.37M | 1.25M | 1.15M |
| EBITDA | (172.6M) | (159.73M) | (105.2M) | (87.95M) | (107.79M) |
| EBITDA Margin | — | -6384.1% | -680.8% | -1055.5% | -1102.9% |
| Operating Income | (173.27M) | (126.03M) | (72.44M) | (91.46M) | (110.5M) |
| Operating Margin | — | -5037.1% | -468.8% | -1097.6% | -1130.6% |
| Interest Income | 172K | 249K | 3.57M | 6.94M | 9.22M |
| Interest Expense | 1.43M | 3.8M | 5M | 102K | 63K |
| Other Income / Expenses | (1.26M) | (39.99M) | (39.13M) | 2.16M | 1.5M |
| Income Before Tax | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Pre-Tax Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (174.52M) | (166.01M) | (111.57M) | (89.3M) | (109M) |
| Net Margin | — | -6635.3% | -722.1% | -1071.6% | -1115.3% |
| EPS (Basic) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| EPS (Diluted) | (4.64) | (3.78) | (0.96) | (0.36) | (0.34) |
| Weighted Avg Shares | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
| Weighted Avg Shares (Diluted) | 37.65M | 43.95M | 116.12M | 250.13M | 319.71M |
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.